TheTechno Optimist.

Otarmeni (DB-OTO)Regeneron Pharmaceuticals—FDA grants accelerated approval to Regeneron's Otarmeni, the first gene therapy for inherited deafnessOtarmeni (DB-OTO)Regeneron Pharmaceuticals—Regeneron presents Otarmeni long-term safety and efficacy data at medical conferences

Regeneron Pharmaceuticals

OTOF gene therapy, monoclonal antibodies, Eylea, Dupixent

USpublicest. 1988regeneron.com (opens regeneron.com)Checked 11 Oct

The brief

Analyst view
  • Regeneron has $10B+ annual revenue, spanning monoclonal antibodies (Eylea, Dupixent), RNA therapeutics, and gene therapies.
  • Otarmeni is the first FDA-approved gene therapy for inherited deafness, delivering OTOF gene to inner ear hair cells.
  • In trials, 80% showed improved hearing; 42% achieved normal hearing levels.

Technical approach

As reported
AAV vector

Engineered virus delivers functional OTOF gene

AAV carries OTOF DNA to inner ear hair cells, which produce otoferlin protein needed for sound transmission.

Delivery

One cochlear infusion under anesthesia

Single procedure like cochlear implant surgery. No repeated doses or systemic toxicity observed in trials.

Mechanism

Otoferlin enables sound transmission

OTOF mutations cause congenital deafness. Gene delivery restores hair cell function and sound perception.

Primer